Just a couple of months after accepting the application, the FDA has approved Takeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before its blockbuster Velcade loses patent protection. That will come sooner rather than later after a federal court ruling in August which could allow generics to hit in 2017, instead of 2022. FierceBiotech story | More